MTI Signs Multi-Year, Non-Exclusive Agreement with U.S. Based Evolution Laboratories
MTI has signed a multi-year, non-exclusive licensing and distribution agreement with U.S. based Evolution Laboratories for its flagship product, PolypDx™, a urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer. This agreement marks the second licensing and distribution secured by MTI in the last year. The non-exclusive licensing and distribution agreement signed between MTI and Evolution Laboratories in association with Lab Express, LLC, provides additional entry points into five western U.S. states including; Nevada, California, Arizona, Utah and Texas.